Murai K, et al. - A phase-II study was conducted to explore the efficacy and safety of dasatinib in patients newly diagnosed with chronic-phase chronic myeloid leukaemia (CML-CP) in Japan (IMIDAS PART 2 study). As per observations, primary treatment of CML-CP with dasatinib resulted in early achievement of MMR and deep molecular response(DMR), particularly in elderly patients, with high safety. In addtion, researchers identified RR-BCR-ABL13m as a more useful predictor of DMR than HT-BCR-ABL1 and BCR-ABL1 international scale (IS).